RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $34
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains a Sector Perform rating on PTC Therapeutics and raises the price target from $32 to $34.
October 04, 2024 | 3:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has increased the price target for PTC Therapeutics from $32 to $34, maintaining a Sector Perform rating. This suggests a modestly positive outlook for the stock.
The increase in price target from $32 to $34 by RBC Capital indicates a slightly more optimistic view on PTC Therapeutics' future performance. Maintaining a Sector Perform rating suggests that the stock is expected to perform in line with the sector, but the raised target could lead to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100